The global immune thrombocytopenia treatment market is experiencing a period of significant development. This situation can be attributed to several factors, including an increasing prevalence of immune thrombocytopenia worldwide and the launch of novel treatment therapies. Furthermore, advancements in diagnostic techniques are supporting earlier d